Skip to main content
SpringerLink
Log in

Future Directions in the Development of New Antitubercular Drugs

Where Do We Go From Here?

  • Leading Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

The global resurgence of tuberculosis and rampant drug resistance have rekindled the need for and interest in the development of new antitubercular drugs. Delineation of the possible drug targets furnished by the various mycobacterial cell components might result in rational approaches to the development of such agents. In the future, molecular genetics might help both in the bioengineering and rapid screening of the activity of new compounds. Collaboration is anticipated between the pharmaceutical industry and academic institutions in these areas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Explore related subjects

Discover the latest articles, news and stories from top researchers in related subjects.

References

  1. Sudre P, ten Dam G, Kochi A. Tuberculosis: a global overview of the situation today. Bull World Health Organ 1992; 70: 149–59

    PubMed  CAS  Google Scholar 

  2. Dolin PJ, Raviglione MC, Kochi A. Global tuberculosis incidence and mortality during 1990–2000. Bull World Health Organ 1994; 72: 213–20

    PubMed  CAS  Google Scholar 

  3. WHO. Laboratory evaluation of drug resistant tuberculosis. Document WHO/TB/93. 171. Geneva: WHO, 1993

    Google Scholar 

  4. WHO. WHO report on the tuberculosis epidemic 1995. Document WHO/TB/95. 183. Geneva: WHO, 1995

    Google Scholar 

  5. Dickinson JM, Mitchison DA. In vitro properties of rifapentine (MDL 473) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle 1987; 68: 113–8

    Article  PubMed  CAS  Google Scholar 

  6. Dhillon J, Dickinson JM, Guy JA. Activity of two long-acting rifamycins, rifapentine and FCE 22807 in experimental murine tuberculosis. Tubercle Lung Dis 1992; 73: 116–23

    Article  CAS  Google Scholar 

  7. Chan SL, Yew WW, Porter JHD, et al. Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals. Int J Antimicrob Agents 1994; 3: 267–74

    Article  PubMed  CAS  Google Scholar 

  8. Tarn CM. Clinical trial of rifapentine in Hong Kong [abstract]. Tubercle Lung Dis 1996; 77: Suppl. 2: S16

    Google Scholar 

  9. Gangadharam PRJ, Ashtekar DR, Farhi DC, et al. Sustained release of isoniazid in vivo from a single implant of biodegradable polymer. Tubercle 1991; 72: 115–22

    Article  PubMed  CAS  Google Scholar 

  10. Sensi P. Approaches to the development of new antituberculosis drugs. Rev Infect Dis 1989; 11: Suppl. 2: S467–70

    Article  PubMed  CAS  Google Scholar 

  11. Agarwal A, Kandpal H, Gupta HP. Tuftsin-bearing liposomes as rifampin vesicles in the treatment of tuberculosis in mice. Antimicrob Agents Chemother 1994; 38: 588–93

    Article  PubMed  CAS  Google Scholar 

  12. Mehta RT, Keyhani A, McQueen TJ. In vitro activities of free and liposomal drugs against Mycobacterium avium — M. intracellulare complex and M. tuberculosis. Antimicrob Agents Chemother 1993; 37: 2584–7

    Article  PubMed  CAS  Google Scholar 

  13. Rook GAW, Steele J, Ainsworth M, et al. Activation of macrophages to inhibit proliferation of Mycobacterium tuberculosis: comparison of the effects of recombinant gamma-interferon on human monocytes and murine peritoneal macrophages. Immunology 1986; 59: 333–8

    PubMed  CAS  Google Scholar 

  14. Wolf SF, Temple PA, Kobayashi M, et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 1991; 146: 3074–81

    PubMed  CAS  Google Scholar 

  15. Stanford JL, Grange JM. The promise of immunotherapy for tuberculosis. Respir Med 1994; 88: 3–7

    Article  PubMed  CAS  Google Scholar 

  16. Onyebujoh PC, Abdulmumini T, Robinson S, et al. Immunotherapy with Mycobacterium vaccae as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa. Respir Med 1995; 89: 199–207

    Article  PubMed  CAS  Google Scholar 

  17. Davies PDO. Tuberculosis in the elderly. J Antimicrob Chemother 1994; 34 Suppl. A: S93–100

    Google Scholar 

  18. Thompson NP, Caplin ME, Hamilton MI, et al. Antituberculosis medication and the liver: dangers and recommendations in management. Eur Respir J 1995; 8: 1384–8

    Article  PubMed  CAS  Google Scholar 

  19. Yew WW, Lee J, Wong PC, et al. Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in the presence of hepatic dysfunction. Int J Clin Pharm Res 1992; XII: 173–8

    Google Scholar 

  20. Kanyok TP, Reddy MV, Chinnaswamy J, et al. Activities of aminosidine (paromomycin) for Mycobacterium tuberculosis and Mycobacterium avium. J Antimicrob Chemother 1994; 33: 323–7

    Article  CAS  Google Scholar 

  21. Kanyok TP, Reddy MV, Chinnaswamy J, et al. In vivo activity of paromomycin against susceptible and multidrug-resistant Mycobacterium tuberculosis and M. avium complex strains. Antimicrob Agents Chemother 1994; 38: 170–3

    Article  PubMed  CAS  Google Scholar 

  22. Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med 1994; 121: 905–11

    PubMed  CAS  Google Scholar 

  23. Young LS, Berlin OGW, Inderlied CG. Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria. Am J Med 1987; 82 Suppl. 4A: S23–6

    Google Scholar 

  24. Rastogi N, Goh KS. In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother 1991; 35: 1933–6

    Article  PubMed  CAS  Google Scholar 

  25. Lalande V, Truffot-Pernot C, Paccaly-Moulin A, et al. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 1993; 37: 407–13

    Article  PubMed  CAS  Google Scholar 

  26. Yew WW, Piddock LJV, Li MSK, et al. In vitro activity of quinolones and macrolides against mycobacteria. J Antimicrob Chemother 1994; 34: 343–51

    Article  PubMed  CAS  Google Scholar 

  27. Yew WW, Kwan SYL, Ma WK, et al. ln-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis. J Antimicrob Chemother 1990; 26: 227–36

    Article  PubMed  CAS  Google Scholar 

  28. Kennedy N, Fox R, Kisyombe GM, et al. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am Rev Respir Dis 1993; 148: 1547–51

    Article  PubMed  CAS  Google Scholar 

  29. Willcox PA. Ofloxacin-based chemotherapy in multiple drug-resistant pulmonary tuberculosis. Drugs 1993; 45 Suppl. 3: S223–4

    Article  Google Scholar 

  30. Schaberg T, Specht C, Stephan H. Use of sparfloxacin for treatment of multi-drug resistant pulmonary tuberculosis [abstract]. Tubercle Lung Dis 1995; 76 Suppl. 2: S86

    Article  Google Scholar 

  31. Yew WW, Wong CF, Lee J, et al. Management of multidrug-resistant tuberculosis (MDR-TB): some experience from Hong Kong [abstract]. Chest 1996; 110 Suppl.: S128

    Article  Google Scholar 

  32. Saito H, Sato K, Tomioka H, et al. In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355). Tubercle Lung Dis 1995; 76: 377–80

    Article  CAS  Google Scholar 

  33. Mor N, Vanderkolk J, Heifets L. Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. Antimicrob Agents Chemother 1994; 38: 1161–4

    Article  PubMed  CAS  Google Scholar 

  34. Klemens SP, Sharpe CA, Rogge MC, et al. Activity of levofloxacin in a murine model of tuberculosis. Antimicrob Agents Chemother 1994; 38: 1476–9

    Article  PubMed  CAS  Google Scholar 

  35. Kennedy N, Fox R, Uiso L, et al. Safety profile of ciprofloxacin during long-term therapy for pulmonary tuberculosis. J Antimicrob Chemother 1993; 32: 897–902

    Article  PubMed  CAS  Google Scholar 

  36. Berning SE, Madsen L, Iseman MD, et al. Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. Am J Respir Crit Care Med 1995; 151: 2006–9

    PubMed  CAS  Google Scholar 

  37. Rastogi N, Ross BC, Dwyer B, et al. Emergence during unsuccessful chemotherapy of multidrug resistance in a strain of Mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis 1992; 11: 901–7

    Article  PubMed  CAS  Google Scholar 

  38. Cambau E, Sougakoff W, Besson M, et al. Selection of a gyr A mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis 1994; 170: 479–83

    Article  PubMed  CAS  Google Scholar 

  39. Dickinson JM, Mitchison DA. In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle 1987; 68: 177–82

    Article  PubMed  CAS  Google Scholar 

  40. Heifets LB, Lindholm-Levy PJ, Flory MA. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am Rev Respir Dis 1990; 141: 626–30

    Article  PubMed  CAS  Google Scholar 

  41. Chan SL, Yew WW, Ma WK, et al. The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with tuberculosis. Tubercle Lung Dis 1992; 73: 33–8

    Article  CAS  Google Scholar 

  42. Sirgel FA, Botha FJH, Parkin DP, et al. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. J Antimicrob Chemother 1993; 32: 867–75

    Article  PubMed  CAS  Google Scholar 

  43. Gonzalez-Montaner LJ, Natal S, Yongchaiyud P, et al. Rifabutin for the treatment of newly diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Tubercle Lung Dis 1994; 75: 341–7

    Article  CAS  Google Scholar 

  44. Schwander S, Rusch-Gerdes S, Mateega A, et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-associated tuberculosis: a single-blind randomized evaluation in Ugandan patients with HIV-infection and pulmonary tuberculosis. Tubercle Lung Dis 1995; 76: 210–8

    Article  CAS  Google Scholar 

  45. O’Brien RJ, Lyle MA, Snider Jr DE. Rifabutin (ansamycin LM-427): a new rifamycin-S derivative for the treatment of mycobacterial diseases. Rev Infect Dis 1987; 9: 519–30

    Article  PubMed  Google Scholar 

  46. Hong Kong Chest Service, British Medical Research Council. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Tubercle Lung Dis 1992; 73: 59–67

    Article  Google Scholar 

  47. Pretet S, Lebeaut A, Parrot R, et al. Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant tuberculosis. Eur Respir J 1992; 5: 680–4

    PubMed  CAS  Google Scholar 

  48. Hirata T, Saito H, Tomioka H, et al. In vitro and in vivo activities of the benzoxazino-rifamycin, KRM-1648, against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995; 39: 2295–303

    Article  PubMed  CAS  Google Scholar 

  49. Jagannath C, Reddy MV, Kailasam S, et al. Therapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis: in vitro, intracellular and in vivo studies. Am J Respir Crit Care Med 1995; 151: 1083–6

    PubMed  CAS  Google Scholar 

  50. Takayama K, Kilburn JO. Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother 1989; 33: 1493–9

    Article  PubMed  CAS  Google Scholar 

  51. Rastogi N, Frehel C, Ryter A, et al. Multiple drug resistance in Mycobacterium avium: is the wall architecture responsible for the exclusion of the antimicrobial agents? Antimicrob Agents Chemother 1981; 20: 666–77

    Article  PubMed  CAS  Google Scholar 

  52. Rastogi N, Goh KS, David HL. Enhancement of drug susceptibility of Mycobacterium avium by inhibitors of cell envelope synthesis. Antimicrob Agents Chemother 1990; 34: 759–64

    Article  PubMed  CAS  Google Scholar 

  53. Heifets LB, Iseman MD, Lindholm-Levy PJ. Combinations of rifampin or rifabutine plus ethambutol against Mycobacterium avium complex: bactericidal synergistic, and bacteriostatic additive or synergistic effects. Am Rev Respir Dis 1988; 137: 711–5

    PubMed  CAS  Google Scholar 

  54. Maurer PJ, Miller MJ. Total synthesis of a mycobactin: mycobactin S2. J Am Chem Soc 1983; 105: 240–5

    Article  CAS  Google Scholar 

  55. Cynamon MH, Palmer GS. In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1983; 24: 429–31

    Article  PubMed  CAS  Google Scholar 

  56. Yew WW, Wong CF, Lee J, et al. Do beta-lactam-beta-lactamase inhibitor combinations have a place in the treatment of multidrug-resistant tuberculosis? Tubercle Lung Dis 1995; 76: 90–2

    Article  CAS  Google Scholar 

  57. Zhang Y, Lathigra R, Garbe T, et al. Genetic analysis of super-oxide dismutase, the 23 kilodalton antigen of Mycobacterium tuberculosis. Mol Microbiol 1991; 5: 381–91

    Article  PubMed  CAS  Google Scholar 

  58. Beaman L, Beaman BL. Monoclonal antibodies demonstrate that superoxide dismutase contributes to protection of Nocardia asteroides within the intact host. Infect Immun 1990; 58: 3122–8

    PubMed  CAS  Google Scholar 

  59. Jacobs WR, Barletta RG, Udani R, et al. Rapid assessment of drug susceptibilities of Mycobacterium tuberculosis by means of luciferase reporter phages. Science 1993; 260: 819–22

    Article  PubMed  CAS  Google Scholar 

  60. Telenti A, Imboden P, Marchesi F, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341: 647–50

    Article  PubMed  CAS  Google Scholar 

  61. Zhang Y, Heym B, Allen B, et al. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992; 358: 591–3

    Article  PubMed  CAS  Google Scholar 

  62. Zhang Y, Young DB. Molecular mechanisms of isoniazid: a drug at the front line of tuberculosis control. Trends Microbiol 1993; 1: 109–13

    Article  PubMed  CAS  Google Scholar 

  63. Banerjee A, Dubnau E, Quemard A, et al. InhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994; 263: 227–30

    Article  PubMed  CAS  Google Scholar 

  64. Bodmer T, Zürcher G, Imboden P, et al. Mutation position and type of substitution in the β-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 1995; 35: 345–8

    Article  PubMed  CAS  Google Scholar 

  65. Moghazeh SL, Pan X, Arain T, et al. Comparable antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoβ mutations. Antimicrob Agents Chemother 1996; 40: 2655–7

    PubMed  CAS  Google Scholar 

  66. Cole ST. Why sequence the genome of Mycobacterium tuberculosis? Tubercle Lung Dis 1996; 77: 486–90

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Tuberculosis and Chest Unit, Grantham Hospital, 125 Wong Chuk Hang Road, Hong Kong

    Wing Wai Yew & Chi Hung Chau

Authors
  1. Wing Wai Yew
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chi Hung Chau
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yew, W.W., Chau, C.H. Future Directions in the Development of New Antitubercular Drugs. Drugs & Aging 10, 405–410 (1997). https://doi.org/10.2165/00002512-199710060-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199710060-00001

Keywords

Search

Navigation